08 Apr Have Your Practice Join the ONLY IRB Study Approved for Regenerative Cell Therapy
Would you like your practice’s regenerative program to be part of an approved IRB protocol? R3 Stem Cell is now offering that option with its recent IRB approved study titled “Safety and Clinical Outcomes Study: Amniotic and Umbilical Cord Tissue Administration for Orthopedic, Neurologic, Urologic, Autoimmune, Cardiac, Renal and Pulmonary Conditions”.
The Institutional Review Board approved protocols include procedures for over a dozen different conditions such as Neuropathy, Arthritis, Erectile Dysfunction, Rheumatoid Arthritis, Lupus, COPD, Heart Failure, Kidney Disease and more. There are several different procedure protocols along with a variety of consent forms and outcome instruments.
What are the benefits of working with R3 Stem Cell on the study? For one thing, patients appreciate that an accredited third party has reviewed the procedures and protocols for safety and to make sure the benefits significantly outweigh any risks. R3 has a full set of research coordinators to work with practices on implementation and data acquisition. There is no need for additional personnel at your practice.
Other benefits include preferred product pricing and access to the R3 Peer to Peer Network that has performed over 10,000 successful stem cell procedures nationwide. R3 has extensive experience over the past seven years with an amazing safety record!
When patients enroll in the IRB, baseline data is obtained to understand where the patient is starting. After the procedure is performed, data is then obtained at regular intervals to look for changes from that baseline. R3’s research staff is heavily involved with each practice who is a co-investigator. Call (844) GET-STEM to obtain additional information about potential participation!